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Abstract
The use of long-term catheterisation to manage insensate bladders, often associated with
spinal cord injury (SCI), increases the risk of microbial colonisation and infection of the uri-
nary tract. Urinary tract infection (UTI) is typically diagnosed and treated based on the cultur-
ing of organisms from the urine, although this approach overlooks low titer, slow growing
and non-traditional pathogens. Here, we present an investigation of the urinary tract micro-
biome in catheterised SCI individuals, using T-RFLP and metagenomic sequencing of the
microbial community. We monitored three neurogenic patients over a period of 12 months,
who were part of a larger study investigating the efficacy of probiotics in controlling UTIs, to
determine how their urinary tract microbial community composition changed over time and
in relation to probiotic treatment regimens. Bacterial biofilms adherent to urinary catheters
were examined as a proxy for bladder microbes. The microbial community composition of
the urinary tract differed significantly between individuals. Probiotic therapy resulted in a sig-
nificant change in the microbial community associated with the catheters. The community
also changed as a consequence of UTI and this shift in community composition preceded
the clinical diagnosis of infection. Changes in the microbiota due to probiotic treatment or
infection were transient, resolving to microbial communities similar to their pre-treatment
communities, suggesting that the native community was highly resilient. Based on these
results, we propose that monitoring a patient’s microbial community can be used to track the
health of chronically catheterized patients and thus, can be used as part of a health-status
monitoring program.
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Introduction
Catheterised patients, particularly those with spinal cord injuries (SCI), are highly susceptible
to microbial colonization and hence are at increased risk of symptomatic infection [1–8]. SCIs
are often associated with neurogenic bladders, a condition in which nerve damage gives rise to
bladder dysfunction, necessitating catheterization. Catheters can facilitate biofilm formation
on their surfaces and this can subsequently provide direct access to the bladder, leading to col-
onization. These biofilms serve as reservoirs for infection by a variety of organisms [8–12].
Indeed, the isolation of multiple organisms at high titers from the urine is not uncommon for
catheterised patients [3,13–16]. Increasingly, it is appreciated that urinary tract infections may
involve non-traditional pathogens or may be caused by multiple infecting organisms [17]. It
may therefore be possible to use molecular approaches to improve our understanding of the
roles of different microorganisms and their roles in symptomatic and asymptomic coloniza-
tion or infection of catheterised patients to better enable strategies to mitigate symptomatic
infections.
DNA fingerprinting techniques such as T-RFLP have proven to be useful in characterising
microbes in soil and marine environments [18,19], and to a lesser extent in humans. For exam-
ple, Wang et al. (2004) monitored the faecal microbiome of two infants during a longitudinal
study using T-RFLP of the 16S rRNA gene and DNA sequencing and found a shift in the com-
munity after weaning compared to a stable composition during breastfeeding [20]. Changes in
the urine microbiomes of renal transplant patients were linked to transplant rejection and
infection episodes, suggesting that such changes in community composition can be predictive
of poor outcomes for patients [21]. For example, a 16S rDNA based analysis of urinary cathe-
ters of non-neurogenic bladders in males showed that the communities varied significantly
between patients [22]. Similar findings were reported in another study of the microbiota of
catheters of patients with neurogenic bladders and additionally reported, that the specific
organisms identified depended on the method used, e.g. T-RFLP or pyrosequencing [23]. The
interpatient variation in microbiome members also holds true for neurogenic and non-neuro-
genic bladders, and often includes organisms that have not previously been described by cul-
turing [24]. What remains to be understood is how those communities change over time,
especially in relation to clinically relevant infections as well as antibiotic and alternative
therapies.
With the rise of multidrug and extremely drug resistant organisms, there is a dire need for
alternative strategies to control UTI, especially for highly at risk patients, such as spinal cord
injury patients. One strategy that has gained attention is the use of probiotics as a type of biore-
gulation or biointerference against UTI. Lactobacilli spp. and Bifidobacteria spp. are the most
commonly investigated probiotics for altering the microflora and preventing disease in the
human host [25,26] and their efficacy is currently being tested for their ability to reduce UTI
associated with neurogenic bladders [27]. Administration of Lactobacillus rhamnosus GR-1
and Lactobacillus reuteri RC-14 orally and intravaginally can alter the composition of the
microflora at intestinal and urogenital sites [28,29]. In vitro studies have shown that catheters
coated with Escherichia coli 83972 resist colonisation by pathogenic Enterococcus faecalis, Pro-
videncia stuartii, lactose negative E. coli and Candida albicans [30,31]. Direct instillation of E.
coli 83972 into the neurogenic bladder is safe and results in successful, but transient, colonisa-
tion [32] and treated subjects experienced fewer incidences of UTI [32,33]. One of the primary
challenges in using E. coli 83972 as a long term therapeutic was its lack of persistence in the
bladders of some patients [32,33]. This highlights the need to monitor and understand changes
in the urogenital microbiome as a function of probiotic treatment as well as the long-term
effects of the probiotic once treatment has stopped.
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Here, we present data from a clinical study on the efficacy of probiotic treatments for the
control of UTIs in neurogenic patients in which we assessed the impact of probiotics on the
host urinary tract flora. Three patients were monitored longitudinally for changes in their uri-
nary microbiome both during and after the probiotic treatment period. Bacteria were identi-
fied and classified by DNA fingerprinting and next generation amplicon sequencing. The
results show that the microbiomes changed in response to treatment and UTI status and sug-
gests that such data can be used to monitor patients’ health status and can be used to tailor
management practices for individuals.
Materials and methods
Ethics statement
Patients were participants in the ProSCIUTTU Clinical Trial, Australian New Zealand Clinical
Trials Registry number ACTRN 12610000512022. All study protocols were approved by the
relevant Human Research Ethics Committees at Prince of Wales Hospital, Royal North Shore
Hospital and Royal Rehab (HREC ref no. 11/036, HREC/10/HARBR/102; SSA/10/HAWKE/
171). Written informed consent was obtained from all participants and samples were de-iden-
tified by assigning them an arbitrary subject number.
ProSCIUTTU clinical trial treatment protocol
Inclusion and exclusion criteria for patient enrolment were as described in the ProSCIUTTU
trial protocol [34]. Three patients from the trial were approached and provided informed
consent for the longitudinal study of their catheter flora. The longitudinal design allowed
for the study of catheter flora during the ProSCIUTTU probiotic treatment period and after-
ward during no treatment. Subjects were selected by convenience sampling on the following
criteria: completion of ProSCIUTTU enrolment before April 2013, allowing sufficient time
for collection and analysis of post-treatment samples, and ease of access. Patients 2 and 3
resided in close proximity to Prince of Wales Hospital, which simplified the logistics of sample
collection.
While enrolled in ProSCIUTTU, patients underwent 6 months of oral treatment with pro-
biotic formulations consisting of Lactobacillus rhamnosus GR-1 with Lactobacillus reuteri RC-
14 or placebo; and Lactobacillus rhamnosus GG (LGG) with Bifidobacterium (BB-12) (CHR
Hansen, Denmark) or placebo, as per the randomisation protocol [34].
Patient 1 received GR1-RC14 active and LGG-BB12 placebo. Patients 2 and 3 received the
GR1-RC14 placebo and LGG-BB12 active. Subjects and investigators were blinded to treat-
ment allocation during enrolment. UTI history was collected for the year prior to ProSCIUT
TU enrolment and patients were contacted fortnightly to monitor UTI status, compliance
with study protocol and changes in medication.
Catheter sample collection
Between the time points of Month 0 (Baseline) and Month 6 of enrolment, an explanted uri-
nary catheter sample was collected from each patient. In addition, samples were collected from
each patient at multiple time points in the post-treatment period, with a goal of six consecutive
samples. The collection of the explanted catheter coincided with the patient’s regular catheter
change and was performed aseptically by trained health personnel. A 5 cm section of the blad-
der end of the catheter was cut using sterile scissors and collected in a sterile container. All
samples were labelled with a patient ID, date and time removed. The catheter was stored at
4˚C, transported laboratory and the adherent community was extracted within 48 h of
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collection. This process was previously shown to have no effect on quantitative counts of
microorganisms [35–38] and hence should not introduce a bias in the data.
Collection of and DNA extraction from catheter biofilms
Under sterile conditions, the catheter was transferred to a falcon tube containing 5 ml of sterile
phosphate buffered saline (PBS) and sonicated in an ultrasonic water bath (Unisonics, Austra-
lia) at 90 kHz for 5 min to dislodge adherent microorganisms. This was followed by vortexing
(Whirli VIB 2, Inter Med, Denmark) for 90 s.
After removal of the catheter from the falcon tube, the cell suspension was centrifuged at
7690 g and 4˚C for 10 min (Universal 320R, Hettich, Germany), the supernatant was discarded
and the biomass was stored at -20˚C. Total DNA was extracted using the FastDNA SPIN Kit
for Soil and the FastPrep Instrument (MP Biomedicals, Santa Ana, CA) according to manufac-
turer’s instructions. The quality of DNA was confirmed by electrophoresis on a 1% (w/v) aga-
rose gel stained with ethidium bromide and the concentration and purity determined by
spectrophotometery (Nanodrop 1000; Thermo Fisher Scientific, MA, USA).
Biofilm/microbial community analysis by T-RFLP
Polymerase Chain Reaction (PCR). The primers 27F (5'-AGR GTT TGA TCM TGG CTC
AG-3') and 536R (5’-GWATTA CCG CGG CKG CTG-3’) were used for amplification of bac-
terial 16S rRNA genes. The 5’ end of the 27F primer was fluorescently labeled with 6-carboxy-
fluorescein (6-FAM). The PCR reaction mixture contained: 25 μL EconoTaq PLUS mastermix
(0.1 units/μL EconoTaq DNA polymerase, Reaction Buffer (pH 9.0), 400 μM dNTP, 3 mM
MgCl2 and PCR Enhancer/Stabilizer (Lucigen, MI, USA); 10 μM each of forward and reverse
primers; 50–100 ng of template DNA and ultrapure water up to 50 μL.
The PCR reactions were performed in a MultiGene Gradient Thermal Cycler (Labnet Inter-
national Inc., NJ, USA) with the following parameters: initial denaturation at 95˚C for 2 min
followed by 30 cycles of denaturation at 95˚C for 30 s, annealing at 55˚C for 30 s and extension
at 72˚C for 1 min. The final extension step was at 72˚C for 10 min. PCR products were purified
using a PureLink PCR Purification Kit (Life Technologies, MA, USA) according to the manu-
facturer’s instructions. Following amplification and purification, the quality of amplified DNA
was confirmed by spectrophotometry (Nanodrop; Thermo Fisher Scientific, MA, USA).
Restriction endonuclease digestion. The fluorescently labelled amplicons were digested
using MspI (New England Biolabs, MA, USA), purified using an Oligo Clean and Concentra-
tor Kit (Zymo Research Corporation, CA, USA), diluted to a concentration of 2 ng/μL and
submitted to the Ramaciotti Centre for Genomics (University of New South Wales, Sydney,
Australia) where the fragments were separated by size on a 3730xl capillary sequencer (Life
Technologies, NY, USA).
T-RFLP data analysis. Raw data files consisting of peak size and intensity were tabulated
and electropherograms were plotted using Peak Scanner Software (Applied Biosystems, CA,
USA). Peak sizes were determined by comparison to the size standard GS600LIZ with a peak
detection range for electropherograms between 30 to 600 bp. The minimum peak height
threshold for baseline detection of peaks was 50 fluorescent units. Samples that were indicated
by Peak Scanner software to be of poor quality were discarded (if < 75% of size standard
fragments were detected). Peak data tables were exported into Excel, reformatted and then
imported into T-RFLP Analysis Expedited Software (T-REX) [39] for noise filtering and align-
ment of peaks between samples.
In T-REX, the noise filtration algorithm used peak area with a standard deviation multiplier
of 3. The peak alignment algorithm rounded off-peak sizes to the nearest integer and clustered
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peaks with a threshold of 0.5. The resultant two-way data matrix of T-RFLPs by samples was
imported into multivariate statistical software package Primer 6 (Primer-E Ltd, Plymouth,
UK). The relative abundance of T-RFLPs was fourth root transformed to reduce the impact of
the more abundant T-RFLPs and to prevent understating the importance of the less abundant
T-RFLPs. Bray Curtis similarity coefficients were calculated for each pair of samples creating a
Bray Curtis similarity matrix. Bray Curtis similarity between samples is based on the relative
abundances of different taxa in the given samples. The similarity data was graphed as two-
dimensional, non-parametric multi-dimensional scaling (MDS) plots for visual exploratory
analysis of differences between samples. Permutational multivariate analysis of variance (PER-
MANOVA) was used to analyse inter- and intra-patient differences in microbial communities.
Microbial community analysis by Illumina sequencing
The microbial community was identified by 16S rRNA gene sequencing of the whole commu-
nity using the Illumina sequencing platform. The primers used for amplification of bacterial
16S rRNA genes were modified 27F and 536R primers with Illumina adapters attached to the
5’ ends as follows:
Forward Primer: 5’ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGA
GTTTGATCMTGGCTCAG
Reverse Primer: 5’ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGWA
TTACCGCGGCKGCTG
Amplicons were verified by electrophoresis on a 1% agarose gel. PCR amplicons were puri-
fied with Agencourt AMPure XP beads (Beckman Coulter Inc., CA, USA). PCR products were
purified by the addition of 20 μL of AMPure XP beads (Beckman) to the amplicons. Purified
PCR amplicons were submitted to the Singapore Centre for Environmental Life Sciences Engi-
neering at Nanyang Technological University, Singapore for processing. Sequencing was per-
formed on a single plate on the Illumina GAIIx platform.
Illumina sequencing data processing. Data was cleaned and analysed using the Quantita-
tive Insights Into Microbial Ecology (QIIME) software package and pipeline [40]. Quality
trimming was done using Cutadapt v1.8, where only truncated reads with a quality score of 20
and length of at least 50 base pairs were kept for downstream analysis. Reads were 300 bp in
length and the minimum quality score required for each base call in a read was 20. Reads were
truncated where two or more consecutive base calls registered a quality score below 20. Addi-
tionally, the algorithm discarded reads with ambiguous base character N in their sequence.
Following quality filtration, there were 11,969,697 paired-end Miseq reads which were suitable
for downstream analysis. The forward and reverse reads were merged into a single read using
FLASH v1.2.1, with minimum overlap of 10 bp and maximum of 300 bp. Paired-end reads
that did not merge were discarded. The sequences have been submitted to Genbank under the
Bioproject ID: PRJNA389364.
Operational Taxonomic Unit (OTU) analysis. Filtered reads were de novo clustered into
OTUs by 97% similarity. The most abundant read in the OTU group was selected as the repre-
sentative sequence and taxonomy was assigned using Greengenes as the reference database
[41,42].
Taxonomic assignment. Chimeras were removed prior to clustering and alignment using
the chimera slayer [43]. Taxonomy was assigned to sequences using UCLUST algorithm
against Greengenes as the reference database [41,42]. Phylogenetic beta-diversity was calcu-
lated using weighted and unweighted UniFrac distances between samples in QIIME [44].
The OTU table of sequencing data containing 270 genera and their abundances for each
sample created in QIIME was imported into Primer 6 software (Primer-E Ltd, Plymouth, UK)
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for visual exploratory analysis of the similarity between samples and for hypothesis testing.
The data matrix of T-RFLP peak size and intensity was also imported into Primer. Taxonomic
profiles were created for each sample from abundance data from both sequencing and T-
RFLP. Visual analysis was done using non-metric, multi-dimensional scaling (MDS) plots.
MDS plots were generated from the ranked Bray Curtis distances between samples. In addition
to MDS plots, Principal Coordinates Ordination (PCO) was used to visualise similarity/differ-
ences between samples. For sequencing data, weighted UniFrac distances, calculated based on
phylogenetic differences between OTUs, were used to assess associations between Patient ID
and community composition. Three-dimensional Principal Coordinates of Analysis PCoA
plots were generated from the weighted UniFrac distance matrix of Illumina sequencing data.
Hypothesis testing for effects of Patient ID and probiotic therapy on flora composition was
done by Permutational Multivariate Analysis of Variance, PERMANOVA [45]. Each factor
(Patient ID and probiotic therapy) was tested separately using single factor PERMANOVA
analysis with unrestricted permutation of raw data and Type III (partial) sums of squares.
Hypothesis testing for differences in microbial diversity was done using students t-tests. A sig-
nificant difference was accepted for p values of 0.05 or less.
Results
Patient demographics and clinical data
A randomised, controlled clinical trial (ProSCIUTTU) was conducted in Australia in 2011–
2014 examining the use of probiotics in the prevention of UTI in the spinal cord injured popu-
lation [27]. Three patients that had completed ProSCIUTTU enrolment before April 2013
allowing sufficient time for collection and analysis of post-treatment samples, were selected for
analysis of their microbiomes (Table 1). Patient 1 had the longest duration of neurogenic blad-
der while Patient 3 had a neurogenic bladder for less than one year. Patients 1 and 3 had supra-
pubic catheters while Patient 2 had an indwelling urethral catheter.
Twenty five samples were analysed, where nine of these were from Patient 1. For this
patient, samples collected during the probiotic treatment were at Months 1, 3 and 6. During
the post-treatment period, an additional 6 samples were collected. Post-treatment sample col-
lection lasted for a period of nine months, commencing 15 months after completion of the
probiotic trial. The average duration of implantation for each catheter for Patient 1 was 57.8
days with a standard deviation of 27.7 days. The variation in duration of implantation times
was due to the development of catheter blockage from crystal formation. For example, post-
treatment sample 4 corresponded to the emergency change of a blocked catheter, 15 days after
insertion. Patient 1 was asymptomatic and experienced no episodes of clinically significant
UTI throughout the entire study.
Seven samples were collected from Patient 2, where only one sample, Month 6, was col-
lected during the probiotic interventional period. Months 0 (pre-treatment) and 3 were not
Table 1. Patient characteristics.
Patient Age (years) Gender Injury level and completeness a Duration of neurogenic bladder Catheter type b
1 50 Male C3 ASIA A 11 years Suprapubic
2 62 Male C5/C6 ASIA B 8 years Indwelling urethral
3 53 Male C4 ASIA B < 1 year Suprapubic
a ASIA, American Spinal Injury Association Impairment Score
b Subprapubic catheters are inserted via an incision through the abdomen; indwelling catheters are inserted via the urethra.
https://doi.org/10.1371/journal.pone.0177633.t001
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collected and six samples were collected in the post-treatment period. The first post-treatment
sample was retrieved 22 months after completion of the probiotic trial, and follow-up contin-
ued over a six-month period. The average duration of implantation for Patient 2 catheters was
25.1 days with a standard deviation of 10 days. The patient suffered from one clinically signifi-
cant UTI during follow-up, most likely E. coli based on urine culture analysis, resulting in an
emergency catheter change but the sample was not collected for the study. As a consequence
of the infection, the patient received antibiotic treatment for the UTI.
Patient 3 supplied nine samples, collected at Months 0 (pre-treatment), and Months 3, 5
and 6 during probiotic treatment. Five samples were collected after completion of the probiotic
trial, and sample collection for the post-treatment period commenced 1 month after the clini-
cal trial and lasted six months. Catheters for Patient 3 were implanted for an average duration
of 31 days with a standard deviation of 4.9 days. The patient experienced no clinically signifi-
cant UTI episodes during the ProSCIUTTU study or in the post-treatment follow-up.
Microbiome composition by patient
Amplicon based sequencing was used to identify and quantify urinary catheter associated
microbial community members and sequences were grouped together as OTUs and reported
when those organisms represented at least 1% of the total community. When the microbiomes
were analysed, Patient 1 was colonised by 10 OTUs, and Patients 2 and 3 had 9 OTUs each.
Across the three patients, Proteobacteria was the dominant phylum (Fig 1A), averaging 79% of
the total bacterial community sequences. Firmicutes were the second most abundant phyla,
with a mean representation of 13%. Across all three patients, Bacteroidetes and Actinobacteria
represented an average of less than 1% each while non-bacterial sequences (e.g. fungal and
human sequences etc) made up an average of 6% of sequences. Patient 1 had the highest aver-
age percentage of non-bacterial taxa at 8%, followed by Patient 2 at 4% and Patient 3 at 6%.
The community members were then classified to genus level. Where the assignment was
not clear at the genus level, the assignment was given as an unclassified genus within the rele-
vant family and are referred to by their OTU designator. The most abundant OTU belonged to
an unclassified genus of the family Enterobacteriaceae/OTU225 (average of 48%), followed by
Providencia (11%), the unclassified genus of the family Alcaligenaceae (10%), and an unclassi-
fied genus of family Enterococcaceae/OTU101 (9%) (Fig 1B). Non-bacterial taxa represented
6% of sequences. Other abundant genera were Pseudomonas and Veillonella, each making up
an average of 4% of the total community across the three patients. Sequences of the family
Enterobacteriaceae/OTU224, genus Haemophilus and order Bacteriodales/OTU49 each repre-
sented on average between 1 and 3% of the total community.
The two taxa that were represented at 1% or more in the flora across all three patients were
the unclassified genus of the family Enterobacteriaceae (OTU225) and the unclassified genus
of the family Enterococcaceae (OTU101). The percentage of Enterococcaceae was highest in
Patient 3 (17%), then Patient 1 (5%) and was lowest in Patient 2 (3%). Patient 2 had the highest
representation of Enterobacteriaceae (85%), followed by Patient 3 (58%) and then Patient 1
(11%).
Inter-patient variation in microbial communities
To examine differences in urinary tract microbiota between patients, T-RFLP and sequencing
data were compared. Examination of the T-RFLP data (Fig 2A) showed that the samples clus-
tered together by patient. For example, all of Patient 2’s samples clustered into a single group
(40% similarity based on Bray-Curtis analysis, red circles), except for the pre-UTI sample (red
circles, arrow) (Fig 2A). Similarly, the samples from Patients 1 and 3 (blue triangles and grey
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Fig 1. Taxonomic distribution of microorganisms in catheterized patients. (A) Phyla as a percentage of taxonomic assignment in urinary
catheter microbiota of the three patients across probiotic treatment and post-treatment time points based on meta-community sequence analysis.
(B) Genera as a percentage of taxonomic assignment for the three patients across probiotic treatment and post-treatment time points based on
meta-community sequence analysis. Only genera with an average representation of 1% or greater are shown. Error bars show standard deviations.
OTUs that were not resolved at the genus level are referred to by their lowest identified phylogenetic classification and OTU number. Only phyla with
a representation of at least 1% in a single individual’s catheter microbiome are shown.
https://doi.org/10.1371/journal.pone.0177633.g001
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squares, respectively) formed separate clusters, and these clusters were distinct for each indi-
vidual. The separation of the samples for patients 1 and 3 into two clusters was associated with
whether the patients were on or off of the probiotic treatment (described in detail below). This
clustering suggests that the communities were significantly different between patients, with a
high intrapatient similarity (PERMANOVA, p = 0.001). Community sequencing data gave
similar results as the T-RFLP data (Fig 2B), which also indicated that the microflora of the
three patients had significant inter-patient differences. Within patient data were similar with
two distinct clusters that correlated with probiotic treatment (PERMANOVA, p = 0.001), with
pre-treatment and post-treatment microflora being similar. While there was a trend of patients
Fig 2. MDS plot showing inter-patient differences in microbial communities of the three patients at
time points of probiotic treatment and post-treatment. Data are shown for T-RFLP analysis (A) and
metacommunity sequence analysis (B). The microbial flora for Patient 1 (Blue triangles), Patient 2 (Red
circles) and Patient 3 (Grey squares) were plotted for each time point collected. The red arrow indicates the
pre-UTI sample for patient 2. The contours group samples with a given percentage of similarity (20%, 40%
and 60%) based on composition and relative abundances of taxa present.
https://doi.org/10.1371/journal.pone.0177633.g002
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having distinct microbiomes, based on the community sequencing data, Patients 2 and 3 were
more similar to each other than to Patient 1, which was the most different from the other two
patients.
To compare the communities between patients, Shannon-Wiener diversity indices were
calculated for the microbial community of each patient based on the Illumina sequence data
(Fig 3). Single factor ANOVA showed that the microbial diversities of the three patients were
significantly different (F of 5.9 > Fcrit of 3.4). Based on two-tailed student’s t-tests, the commu-
nity diversity indices for Patients 1 and 3 were not significantly different (t Stat 0.98 < t Criti-
cal two-tail 2.13). In contrast, the diversity of the microbiota for Patient 2 was significantly
different from that of Patient 1 (t Stat 3.22> t Critical two-tail 2.23) and was also significantly
different from Patient 3 (t Stat -2.22< -t Critical two-tail 2.18). Overall, Patient 2 had lower
microbial diversity, but higher variance, compared to Patients 1 and 3. Interestingly, Patient 2
had a history of recurrent symptomatic UTI, while Patients 1 and 3 did not. It should also be
noted that Patient 2 had an indwelling urethral catheter, while Patients 1 and 3 had suprapubic
catheters.
Changes in microbial community composition during vs after pro-biotic
intervention
As indicated above, the microbial communities of each patient tended to form two distinct
clusters that were differentiated by probiotic treatment. Therefore, to determine if a patient’s
microbiome differed during probiotic therapy compared to post-probiotic treatment, samples
of each patient were examined across time points using both T-RFLP and sequencing ap-
proaches. The results were compared using MDS plots and Principal Coordinates plots and
PERMANOVA was used to test for statistical significance.
For Patient 1, three samples were collected during the probiotic treatment at Months 1, 3
and 6 respectively (green triangles). Six samples were collected from the post-treatment
Fig 3. Shannon diversity indices of the three patients at the genus level from meta-sequencing data.
https://doi.org/10.1371/journal.pone.0177633.g003
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follow-up (non-green triangles). MDS plots showed temporal differences between probiotic
(green triangles) and post-probiotic samples (non-green triangles). Comparison of the com-
munities by T-RFLP and by sequence analysis by MDS plot (Fig 4A and 4B) both indicated
that there was a significant difference between the communities during and post probiotic
intervention (p = 0.022 for T-FRLP and p = 0.012 for sequencing data, PERMANOVA). This
was especially clear for the 16S sequence data where the communities segregated into two
Fig 4. The microbial community composition from Patient 1 during and after probiotic treatment. (A) Samples and time line for Patient 1. MDS plot
of the microbial flora from Patient 1 based on T-RFLP (B) and Illumina sequencing data (C). The green triangles represent samples collected from October
2011 to March 2012 corresponding to Months 1, 3 and 6 of probiotic treatment. All other samples were collected at six time points post-treatment, between
June 2013 and March 2014. (D) Microbiome composition at the genus level for Patient 1 during and after probiotic treatment based on Illumina sequencing
data. The three samples on the left were collected from October 2011 to March 2012 corresponding to Months 1, 3 and 6 of probiotic treatment. The other
samples were collected at six time points in the post-treatment period, between June 2013 and March 2014. Only OTUs representing at least 1% of the total
community are shown. OTUs that were not resolved at the genus level are referred to by their lowest identified phylogenetic classification.
https://doi.org/10.1371/journal.pone.0177633.g004
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distinct groups based on treatment (green triangles on the right in Fig 4B) or no treatment
(samples on the left in Fig 4B).
To further understand the differences in communities between the samples collected at dif-
ferent time points, the community sequence data were examined based on changes in OTUs at
the genus level for each time point. Based on OTUs that were present at>1% of the total com-
munity, 9 different bacterial OTUs were identified at the genus level during the probiotic treat-
ment (October 2011 to March 2012) and the follow-up periods (June 2013 to March 2014) (Fig
4C). During probiotic treatment, the dominant taxa for Patient 1 were OTUs 224 and 225,
both of which correspond to the family Enterobacteriaceae at an average of approximately 27%
each and OTU254 of genus Pseudomonas at an average of 19% (Fig 4). When probiotic treat-
ment was stopped, the microbiomes changed and were dominated by OTU233 of genus Provi-
dencia at 44% and OTU183 of family Alcaligenaceae at 42%, both of which were undetectable
during the probiotic treatment period (Fig 4C). Additionally, non-bacterial taxa declined from
an average of 16% during probiotic treatment to 4% when treatment was stopped.
For Patient 2, there was only one sample collected during probiotic treatment (green trian-
gle) and this was at Month 6. Six samples were collected from the post-treatment follow-up
(non-green triangles). MDS plots showed no spatial separation of the probiotic sample repre-
sented by the green triangle, from the post-probiotic samples (Fig 5A and 5B). However, there
was spatial separation of one sample from the others, represented by the inverted blue triangles
in Fig 5A and 5B. This sample was collected in September 2013, prior to a clinically significant
UTI, which occurred in early October 2013. This pre-UTI sample segregates from samples col-
lected at non-UTI time points, suggesting that there was a disturbance in the microbial com-
munity associated with the onset of symptomatic infection.
Community sequence data was examined for further investigation of the differences in
communities between the samples collected at different time points, in particular changes in
types and relative abundances of OTUs at the genus level. Based on a sub-analysis of the OTUs
that were present at>1% of the total community for patient 2, eight different bacterial genera
over the probiotic treatment period (based on Month 6 sample of Nov 2011) and the follow-
up periods (September 2013 to February 2014) as shown in Fig 5C. The dominant taxon was
OTU 225 from the family Enterobacteriaceae, representing an average of 85% of the total com-
munity. Whilst Enterobacteriaceae was dominant at all time points, it decreased to 53% in the
pre-UTI sample of September 2013 (Fig 5C). The microbial community of the pre-UTI sample
also showed increased diversity of OTUs, and was the only sample with the presence of Veillo-
nella, representing 21% of the community, and order Bacteroidales at 16%. The pre-UTI com-
munity also has 3% of the family Enterococcaceae and 2% of phylum Bacteriodes. Thus, in
contrast to patients 1 and 3, patient 2 appeared to have a much higher proportion of Bacterio-
detes and Actinobacteria.
For Patient 3, there were four samples collected during the probiotic interventional period,
at Month 0 (Pre-treatment) and at Months 3, 5 and 6 of treatment (Fig 6). The probiotic in-
terventional period was between November 2012 and April 2013 (green triangles), and the
patient was sampled at five time points after ceasing treatment (non-green triangles), from
May to October 2013. MDS plots (Fig 6) showed temporal differences between probiotic treat-
ment (green triangles) and post-treatment samples (non-green triangles). Comparison of the
communities by T-RFLP and by sequence analysis (Fig 6A and 6B) indicated that there was a
difference in the communities during probiotic treatment versus no treatment, although that
difference was not statistically significant (p = 0.099 for T-RFLP data and p = 0.081 for the
sequencing data, PERMANOVA). The difference between communities was especially clear
for the sequence based data where the communities segregated into two distinct groups based
on treatment (Months 3 and 5 samples on the left in Fig 6B) or no treatment (samples on the
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right, including the Pre-treatment sample in Fig 6B). Surprisingly, the sample collected at
Month 6 (green triangle, Apr 13) of probiotic treatment appeared to be similar to the no treat-
ment samples (non-green triangles) (Fig 6A and 6B).
To further understand the differences in communities between the samples collected at dif-
ferent time points, the community sequence data was examined based on changes in OTUs at
the genus level for each time point. Eight different bacterial OTUs were identified at the genus
level (Fig 6C) over the probiotic treatment period (November 2012 to April 2013) and the fol-
low-up period (May 2013 to October 2013). The dominant taxon during probiotic treatment
(at Months 3 and 5) was Veillonella, representing an average of 39% of the total community
Fig 5. The microbial community composition from Patient 2 during and after probiotic treatment. (A) Samples and time line for Patient 2. MDS
plot of the microbial flora from Patient 2 during and after probiotic treatment based on T-RFLP (B) and Illumina sequencing data (C). The green triangle
represents the sample collected in November 2011 at Month 6 of probiotic treatment. All other samples were collected post-treatment between September
2013 and February 2014. The plot also shows time points prior to and after UTI occurrence and antibiotic treatment between September and October 2013.
D. Microbial community composition at the genus level for Patient 2 during and after probiotic treatment, and prior to and after UTI occurrence based on
Illumina sequencing data. The sample on the left was collected in November 2011 corresponding to Month 6 of probiotic treatment. The other samples were
collected at six time points in the post-treatment period, between September 2013 and February 2014. The September 2013 sample was at a time point
prior to UTI. Only OTUs representing at least 1% of the total community are shown. OTUs that were not resolved at the genus level are referred to by their
lowest identified phylogenetic classification.
https://doi.org/10.1371/journal.pone.0177633.g005
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(Fig 6C). In contrast, before and after probiotic treatment, Veillonella represented an average
of 0.5% of the microbial community. During non-treatment periods, the community was
instead dominated by taxa of the family Enterobacteriaceae (OTU 225) at an average of approx-
imately 74% (Fig 6C). During probiotic treatment, Enterobacteriaceae (OTU 225) declined
sharply, representing 0.5% of the community. Another change during probiotic treatment was
Haemophilus, which increased dramatically at Months 3 and 5 (average representation of 14%)
Fig 6. The microbial community composition from Patient 3 during and after probiotic treatment. (A) Samples and time line for Patient 3. MDS
plot of the microbial flora from Patient 2 during and after probiotic treatment based on T-RFLP (B) and Illumina sequencing data (C). The four green
triangles represent the samples collected during the probiotic interventional period between November 2012 and April 2013, with November being the
baseline time point examined. All other samples were collected at five post-treatment time points between May and October 2013. D. Microbial flora
composition at the genus level for Patient 3 during and after probiotic treatment based on Illumina sequencing data. The samples collected from
November 2012 to April 2013 correspond to Month 0 (Pre-treatment), and Months 3, 5 and 6 of probiotic intervention. The post-treatment samples were
collected at five time points between May 2013 and October 2013. Only OTUs representing at least 1% of the total community are shown. OTUs that were
not resolved at the genus level are referred to by their lowest identified phylogenetic classification.
https://doi.org/10.1371/journal.pone.0177633.g006
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compared to time points of no-treatment (not detectable, Fig 6C). Pseudomonas was also more
abundant during Months 3 and 5 of probiotic treatment (13%), compared to no-treatment
time points (4%, Fig 6C). Interestingly, the community at Month 6 of treatment (Mar 2013)
was more similar to that of the non-treatment time points than it was to the samples collected
during treatment. Enterococcaceae (OTU 101) was present at all time points, at an average of
17% of the total community.
Discussion
This study compared urinary catheter communities of three male patients over time, with
the aims of identifying the constituent microbial community of the neurogenic bladder and
exploring inter-individual differences in microbiota as well as identifying intra-individual
changes relating to probiotic therapy and clinically significant UTI episodes. T-RFLP and
metacommunity amplicon sequencing were used to profile microbial communities. The key
findings of the study were that the microbiota of catheters from patients with neurogenic
bladders appeared to be diverse and patient specific, suggesting that there was no consensus
microbiome that can be used to define a healthy or diseased state, based on the limited number
of patients tested here. This is consistent with previous studies of urine from healthy males in
which a universal microbial community profile could not be identified by sequencing [24,29,
46,47]. Sequencing of urine from individuals with neurogenic bladders [21,48] and non-neu-
rogenic bladders [49] also revealed patient-to-patient variation in urinary tract communities.
This trend has also been reported for gut communities [50,51]. However, in our study, the
composition of the microbiota all three patients also changed as a result of disturbances, in-
cluding the intake of probiotics or the onset of symptomatic UTI. This preliminary data sug-
gests that changes in an individual’s catheter associated microbiome has the potential to be
used to monitor health status.
In two of three patients, probiotic therapy correlated with a change in the individual’s cath-
eter associated microbial community. In Patients 1 and 3, the community observed during
probiotic treatment clustered separately from their post-treatment microbiota. However, there
was no difference observed between probiotic-associated and non-probiotic microorganisms
for Patient 2. It is important to note that there was only one sample from the probiotic treat-
ment period for Patient 2, making the study underpowered for testing the effect of the probi-
otic treatment. For Patients 1 and 3, while there was a distinct impact of probiotic treatment
on the microbial community, the changes were transient. When treatment ceased, the patient’s
microbial community profile shifted away from the probiotic-associated profile to the pre-pro-
biotic profile for Patients 1 and 3. In Patient 3, this shift back to a pre-probiotic profile was
seen as early as one month after stopping treatment. It is also possible that these differences
between Patients 1 and 3 and Patient 2 is related to the site of catheterization and this should
be controlled for in future studies, with increased patient numbers. Closer scrutiny of Patient
3’s samples also revealed that at Month 6 of probiotic treatment, the microbial community
resembled the post-treatment community rather than probiotic microbiota. This observation,
coupled with data from follow-up contact, suggested that Patient 3 was non-compliant with
the treatment at this time point. Thus, the observation that the community changes depending
on whether a patient was taking oral probiotic or not, suggests that it may be possible to moni-
tor compliance with probiotic therapy by molecular profiling of urinary tract flora in this
patient group by using the catheter associated micoorganisms as a proxy.
The change in the composition of microorganisms observed after ingesting probiotics is
consistent with previous literature showing that orally administered L. rhamnosus GR1 and L.
fermentum RC14 induce changes in vaginal flora [52]. In particular, treatment with GR1-RC14
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resulted in increased levels of Lactobacilli in vaginal flora, and a decreased abundance of yeast
species when examined by culturing of vaginal swabs [52]. Another study focusing the faecal
community of infants over time by T-RFLP demonstrated that the faecal microbiomes were
different between infants and that community composition varied during breastfeeding com-
pared to when the infant was weaned. Enterobacteriaceae were particularly dominant during
breastfeeding but declined after weaning [20]. One additional implication from our study is
that orally delivered dietary treatments such as probiotics do influence the catheter-associated
microbiota within the urinary tract of spinal cord patients.
Our data also suggest that orally delivered probiotic strains can alter the microbiota of the
urogenitral tract in a relatively short time frame. Further, once treatment was stopped, the
patient’s catheter community returned to the pre-treatment community composition, demon-
strating that the bacterial composition of this niche is relatively stable and resilient. This obser-
vation is consistent with previous studies suggesting that probiotic strains do not colonise the
bladder over the long-term [32,53,54]. The lack of a long term impact of probiotic treatment
has also been reported for the intestinal community [55]. For example, within two weeks fol-
lowing oral administration of probiotic Bifidobacterium animalis, that species was almost
undetectable in the faeces [56]. Thus, our study supports evidence that probiotics have a transi-
tory effect on the composition of urogenital flora, and that long-term colonisation of the host
with probiotic strains is challenging. It further demonstrates that sequencing or fingerprinting
methods can be used to track treatment compliance as well as the effect of such treatments on
the microbial communities of individual patients. As noted above, the limited number of
patients reported here represents preliminary data that would support more detailed investiga-
tion of these questions in the future.
Patient 2 experienced one clinically significant UTI that was correlated with a concomitant
change the microbial composition on the catheter just prior to the UTI. After antibiotic treat-
ment and resolution of the UTI (October), the community shifted back to a non-infected pro-
file and remained stable as long as the patient was asymptomatic (October to February). This
indicates that the individual’s microbial community may change or increase in diversity prior
to UTI and is consistent with reports of microbial changes in the urinary tract prior to symp-
tomatic UTI [57]. While it was determined by culturing that the patient was colonized with a
multi-resistant strain of E. coli, although this organism was not detected in the sequencing
data. This may be a due to the limitation of short read amplicon sequencing to resolve organ-
isms at the species level or it could also reflect that, while E. coli was present, it was not the
dominant organism associated with the catheter or was below detection limits. None the less,
the study highlights the potential to use molecular approaches to track therapeutic compliance
and may be predictive of infection, based on those changes to an individual’s catheter associ-
ated microbial community.
For each sample examined in this study, we observed concordance between the microbial
community differences identified by T-RFLP and sequencing. Both methods detected a sig-
nificant difference in communities between individuals as tested by PERMANOVA and the
T-RFLP and Illimuna sequencing produced similar spatial separation of samples by patient
and by time point. While T-RFLP has been widely used in microbial ecology (Mills et al.,
2003), it has been used less extensively in human medicine. However, the work presented here
shows that T-RFLP is sensitive enough to monitor changes in urinary tract flora. Compared
to sequencing approaches, T-RFLP is relatively inexpensive, rapid to perform and can be sim-
pler to interpret and hence may be suitable approach to monitor patients that are chronically
catheterized, such as neurogenic patients. Thus, either T-RFLP or amplicon sequencing could
be routinely performed on catheters upon their routine change. This would allow for the pat-
tern of the community to be tracked over time and changes in that pattern could potentially
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indicate a disturbance in the community, e.g. invasion by a potential pathogen. This informa-
tion could be used to as a management tool by clinicians to determine whether to change cath-
eters more frequently or pre-emptive antibiotic therapy.
In summary, the data presented here highlight that each of the three patients were colonized
by a community that was unique to the individual, and few organisms were shared across the
three patients. Whilst the study population was small, the results from this longitudinal study
of neurogenic patients undergoing probiotic therapy suggest that the catheter associated com-
munity was dynamic, where significant changes in the community composition were observed
following the introduction of probiotic strains and changes in UTI status. Further, the results
showed that the individual’s microbial community was significantly different on and off probi-
otic treatment. The effect of probiotics on the urinary tract flora was transient, supporting evi-
dence that long-term colonisation of the host with probiotic strains is difficult to establish.
Thus, to realise the potential benefits of oral probiotics in the long term, it may require contin-
uous administration of the treatment. While there was some evidence of change in the micro-
bial composition prior to symptomatic UTI, further studies are required with a larger cohort
of participants, and sampling of the urinary microbiome pre-, during and post-infection. This
will be useful in determining the changes in microbiome structure that predict UTI. Finally,
the study demonstrates the potential of molecular methods, i.e. T-RFLP or metacommunity
sequencing, to monitor individual patient health and suggests that these methods could repre-
sent an important tool in the management of UTIs, especially for chronically catheterized
patients.
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